ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1184

Does Blocking IL-17 Treat Recalcitrant Uveitis? Explorative Study on the Use of Ixekizumab to Manage Patients with Uveitis.
Abstract Number: 2087

Does Carbamazepine Impact Risk of Developing Osteoarthritis? Results of a Real-World Data Analysis
Abstract Number: 1937

Does Combining Standard MRI-Based Scores with Radiographic Trabecular Bone Texture Biomarkers Improve Predictive Performance for Radiographic Knee Osteoarthritis Progression?
Abstract Number: 0896

Does complement product C5a and its receptor C5a receptor 1 play a role in giant-cell arteritis?
Abstract Number: 1679

Does First-Line b- or tsDMARDs Choice Influence Progression to Difficult-to-Treat Rhumatoid arthritis? Insights from our longitudinal RA UCLouvain Brussels cohort
Abstract Number: 1340

Does Moderate Alcohol Use Lower Disease Activity Among Patients with Rheumatoid Arthritis?
Abstract Number: 2392

Does Obesity Influence Disease Activity and Biomarkers in Systemic Lupus Erythematosus Patients?: A Retrospective Study
Abstract Number: 1649

Does Physical Activity Differ Among those with Autoimmune vs Non-Autoimmune Rheumatic Diseases?
Abstract Number: 1232

Does Social Support Reduce Bodily Pain among African American Women with SLE?: Findings from a Randomized Controlled Trial
Abstract Number: 0748

Does The Number Of Arteries Affected At The Disease Onset Predict Relapses Of Giant Cell Arteritis?
Abstract Number: 2090

Don’t Throw Out X-Rays! Radiographic Osteoarthritis Severity is Prognostic for Onset of Frequent Knee Pain
Abstract Number: 1302

Dose Adjustment was Necessary in Patients with Cryopyrin-Associated Periodic Syndrome Switching from Anakinra to Canakinumab
Abstract Number: 1269

Dress for success: Influence of Rheumatologist Demographics and Attire on Patients with Chronic Inflammatory Arthritis Perceptions
Abstract Number: 2419

Dried Blood Spots for Remote ANA and Autoantibody Screening
Abstract Number: 0475

Drug Discontinuation in Inflammatory Arthritis Following Mandatory Non-Medical Switching from Originator to Biosimilar in Quebec, Canada

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].